Who is affected by this change?

This affects Independence Blue Cross Dermatology, Oncology providers on Commercial plans.

When does this change take effect?

This change is effective Mar 4, 2026.

Back to dashboard

CommercialCoverageMedium impact

07.07.03o, Photodynamic Therapy (PDT) Using Levulan® Kerastick® or Ameluz® (Aminolevulinic Acid HCl [ALA])

Independence Blue Cross·Dermatology, Oncology·Pharmacy

Effective date

Mar 4, 2026

We identified it

Jun 19, 2026

Days to comply

—

Summary

Insurance policy for Photodynamic Therapy (PDT) using Levulan® Kerastick® or Ameluz® has been reissued with an effective date of March 4, 2026. This is a reissue of existing policy 07.07.03o under the pharmacy category for commercial plans.

Action Required

Action needed

Before March 4, 2026: Billing team should review the updated PDT policy 07.07.03o for any changes to coverage criteria, documentation requirements, or billing procedures for Levulan® Kerastick® or Ameluz® treatments. Monitor for the full policy details when published to identify specific billing changes.

Related policy hubs

Independence Blue Cross policies Dermatology Oncology